Daniel Lochner Biography and Net Worth

Mr. Lochner joined as our Chief Financial Officer in June 2024. Mr. Lochner most recently served as Chief Financial Officer and Chief Business Officer for the Eye Care Division of Viatris Inc. (Nasdaq: VTRS), a global healthcare company, from 2023 to 2024. Prior to Viatris, Mr. Lochner was the Chief Financial Officer and Chief Business Officer of Oyster Point Pharma, Inc (Nasdaq: OYST), a biotechnology company that was acquired by Viatris in 2023, from 2019 to 2023 where he lead a successful initial public offering, other equity and debt financings, the transition to a commercial-stage company and the acquisition to Viatris. Previously, Mr. Lochner was a Managing Director within the Investment Management Division of Goldman, Sachs & Co (NYSE: GS) where he served as a lead equity portfolio manager and healthcare investor for various fund strategies. Mr. Lochner joined the Investment Management Division of Goldman, Sachs & Co in 2005 as an equity investor, a position he maintained during his tenure at the firm. Mr. Lochner received a B.A. in Economics from the University of Richmond and an M.B.A. from Columbia University.

What is Daniel Lochner's net worth?: The estimated net worth of Daniel Lochner is at least $96.86 thousand as of February 5th, 2025. Lochner owns 4,617 shares of Tectonic Therapeutic stock worth more than $96,865 as of December 5th. This net worth approximation does not reflect any other investments that Lochner may own. Learn More about Daniel Lochner's net worth.
How do I contact Daniel Lochner?: The corporate mailing address for Lochner and other Tectonic Therapeutic executives is 100 TECHNOLOGY SQUARE 6TH FLOOR, CAMBRIDGE MA, 02139. Tectonic Therapeutic can also be reached via phone at 617-914-8420 and via email at [email protected]. Learn More on Daniel Lochner's contact information.
Has Daniel Lochner been buying or selling shares of Tectonic Therapeutic?: Daniel Lochner has not been actively trading shares of Tectonic Therapeutic during the last ninety days. Most recently, on Wednesday, February 5th, Daniel Lochner bought 4,617 shares of Tectonic Therapeutic stock. The stock was acquired at an average cost of $54.14 per share, with a total value of $249,964.38. Following the completion of the transaction, the chief financial officer now directly owns 4,617 shares of the company's stock, valued at $249,964.38. Learn More on Daniel Lochner's trading history.
Who are Tectonic Therapeutic's active insiders?: Tectonic Therapeutic's insider roster includes Daniel Lochner (CFO), and Timothy Springer (Director). Learn More on Tectonic Therapeutic's active insiders.
Are insiders buying or selling shares of Tectonic Therapeutic?: In the last year, Tectonic Therapeutic insiders bought shares 5 times. They purchased a total of 234,607 shares worth more than $8,955,655.40. The most recent insider tranaction occured on April, 11th when Director Timothy A Springer bought 9,478 shares worth more than $154,586.18. Insiders at Tectonic Therapeutic own 38.0% of the company. Learn More about insider trades at Tectonic Therapeutic.
Information on this page was last updated on 4/11/2025.

Daniel Lochner Insider Trading History at Tectonic Therapeutic

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/5/2025	Buy	4,617	$54.14	$249,964.38	4,617

Daniel Lochner Buying and Selling Activity at Tectonic Therapeutic

Tectonic Therapeutic Company Overview

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Today's Range

Now: $20.98

$19.56

$21.50

50 Day Range

MA: $17.95

$14.91

$21.47

2 Week Range

Now: $20.98

$13.70

$61.07

Volume

290,375 shs

Average Volume

401,310 shs

Market Capitalization

$392.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.65